danicamtiv

Phase 2Small molecule

Bristol-Myers Squibb

danicamtiv is one of 46 small molecule programs targeting Heart Failure. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Heart FailureActive, not recruiting

Dilated CardiomyopathyActive, not recruiting

Heart FailurePhase 1

Active, not recruiting

Dilated CardiomyopathyPhase 2

Active, not recruiting

Competition

Competitive Landscape

687 competitors in Heart Failure

#DrugCompanyPhaseTrials

Amidate

Pfizer

Preclinical

1 2

Medrol

Pfizer

Preclinical

1 3

Zemplar

Savaysa

Bystolic

VVitae Pharmaceuticals Inc., an Allergan affiliate

Preclinical

4 6

Activase

Roche

Preclinical

—7

Zoloft

VViatris Specialty LLC

Preclinical

2 8

Xifaxan

SSalix

Preclinical

2 9

danicamtiv

Bristol-Myers Squibb

Phase 2

1 10

Tamiflu

CConrado Roberto Hoffmann Filho

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

PreclinicalRecruiting

Dilated Cardiomyopathy

NCT07210723

Clinical

Trials by Indication[1]

Dilated Cardiomyopathy2 trials

Exploratory Study of Danicamtiv in Patients With Primary Dilated Cardiomyopathy (DCM) Due to Genetic Variants or Other Causalities

Terminated· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT04572893·41 enrolled

A Phase 2b/3, Adaptive, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy

Recruiting·KKardigan, Inc.·Preclinical·NCT07210723·332 enrolled

ART1 trial

A Study to Evaluate the Effect of Co-administration of Itraconazole or Diltiazem on the Single-dose of Danicamtiv in Healthy Participants

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT05162222·30 enrolled

Drug1 trial

A Study to Evaluate the Safety, Tolerability, and Drug Levels of Danicamtiv in Healthy Japanese and Caucasian Participants

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT05806359·33 enrolled

Biological Availability1 trial

A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT06027437·21 enrolled

Heart Failure1 trial

A Study to Assess the Effect of Danicamtiv on the Drug Levels of Midazolam in Participants With Stable Heart Failure

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT05952089·13 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for danicamtiv. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — danicamtiv compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for danicamtiv. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bristol-Myers Squibb company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Bristol-Myers Squibb

danicamtiv

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Dilated Cardiomyopathy2 trials

ART1 trial

Drug1 trial

Biological Availability1 trial

Heart Failure1 trial

References

Drug Info

Quick Facts

Related News